Assessing skin blood flow responses to different heating temperatures
Comparing Approaches to Assess Nitric Oxide-dependent Cutaneous Vasodilation
EARLY_PHASE1 · University of Iowa · NCT06499844
This study is testing whether heating the skin to 39°C or 42°C helps us better understand how nitric oxide affects blood flow in small blood vessels.
Quick facts
| Phase | EARLY_PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 56 (estimated) |
| Ages | 18 Years to 30 Years |
| Sex | All |
| Sponsor | University of Iowa (other) |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT06499844 on ClinicalTrials.gov |
What this trial studies
This study compares two methods of assessing nitric oxide-dependent cutaneous vasodilation by examining skin blood flow responses to local heating at 39°C and 42°C. The researchers utilize a minimally invasive technique called intradermal microdialysis to deliver pharmaceutical agents and analyze microvascular function in a small area of the skin. The goal is to determine which temperature provides a more accurate measurement of nitric oxide's role in blood vessel dilation. This could enhance our understanding of endothelial function and microvascular health.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy men and women aged 18-30 years.
Not a fit: Patients with unstable chronic diseases or those on medications affecting microvascular function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for assessing microvascular function, which may benefit patients with vascular-related conditions.
How similar studies have performed: While there has been limited direct comparison of these heating protocols, the approach is innovative and could provide new insights into microvascular assessment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * men and women * 18-30 years of age Exclusion Criteria: * Current or recent (within 8 wks) use of medication that could conceivably alter microvascular function \[including (but not limited to) stimulants, antihypertensives, HMG-CoA reductase inhibitors\] * Changes or alterations in medication status (starting a new, additional, or different medication or changing the dose of a current medication) * Unstable or diagnosed chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease (e.g., hypertension, heart disease, diabetes, hyperlipidemia, psoriasis) * Body mass index \<18.5 or \>35 kg/m2 * Pregnancy (including a positive urine pregnancy test) or breast-feeding * Known allergies to pharmacological agents or study drugs * Non-English-speaking. Participants need to understand English to follow instructions and comply with procedures conducted during the screening and experimental visits.
Where this trial is running
Iowa City, Iowa
- University of Iowa — Iowa City, Iowa, United States (RECRUITING)
Study contacts
- Study coordinator: Anna Stanhewicz, PhD
- Email: anna-stanhewicz@uiowa.edu
- Phone: 3194671732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Endothelial Function